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Abstract 
Objective: The national population-based colorectal cancer (CRC) screening programme in Hungary was 
initiated in December 2018. We aimed to evaluate the current programme and investigate the costs and 
benefits of potential future changes to overcome the low coverage of the target population.  
Methods: We performed an economic evaluation from a healthcare payer perspective using an 
established micro-simulation model (Microsimulation Screening Analysis-Colon). We simulated costs and 
benefits of screening with fecal immunochemical test in the Hungarian population aged 50-100 years, 
investigating also the impact of potential future scenarios which were assumed to increase invitation 
coverage: improvement of the IT platform currently used by GPs or distributing the tests through 
pharmacies instead of GPs.  
Results: The model predicted that the current screening programme could lead to 6.2% CRC mortality 
reduction between 2018 and 2050 compared to no screening. Even higher reductions, up to 16.6%, were 
estimated when tests were distributed through pharmacies and higher coverage was assumed. This 
change in the programme was estimated to require up to 26 million performed fecal immunochemical 
tests and 1 million colonoscopies for the simulated period. These future scenarios have acceptable cost-
benefit ratios of €8,000-€8,700 per life-years gained depending on the assumed adherence of invited 
individuals.  
Conclusions: With its limitations, the current CRC screening programme in Hungary will have a modest 
impact on CRC mortality. Significant improvements in mortality reduction could be made at acceptable 
costs, if the tests were to be distributed by pharmacies allowing the entire target population to be invited.  
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Introduction 1 
Colorectal cancer (CRC) is a major health problem in Hungary, where mortality rates are among the 2 
highest in Europe and an increasing trend in incidence was projected due to the aging population.(1-3) 3 
CRC screening can reduce cancer-specific mortality significantly and might also lead to a reduction in all-4 
cause mortality.(4, 5) However, screening could also result in certain harms (6) and, therefore, expected 5 
net benefit should be assessed before implementing CRC screening at population level.(7) In Hungary, 6 
multiple pilot screening programmes were conducted with moderate success, considering screening and 7 
follow-up participation rates.(8) After these pilots, the national population-based organized CRC screening 8 
programme was initiated in December 2018, offering biennial fecal immunochemical test (FIT) screening 9 
to individuals aged 50-70 years (positivity cut-off: 20 µg/g).(9) The invitation process for the target 10 
population is centrally coordinated by the National Public Health Institute. This involves sending 11 
invitations to all individuals associated with GPs who are participating in the programme. GPs volunteered 12 
to participate in the programme for extra funding, which is a fixed fee per screened individual. The invited 13 
individuals can collect the FIT kit from their GP. 14 
Some organizational barriers might limit the performance of the current screening programme as shown 15 
by the EU-TOPIA project framework.(10) GPs are generally overwhelmed in Hungary as the country has 16 
been suffering from a significant workforce crisis in primary care in the past two decades, which is 17 
indicated by the decreased inflow of GPs and by the fact that almost half of GPs are aged over 55 years.(11) 18 
Hence, not all GPs have decided to have an active part in the organized CRC screening programme for 19 
reasons including the additional workload and the user-unfriendly IT platform of the programme. Thus, 20 
only eligible individuals whose GPs had volunteered to participate were invited in the first implementation 21 
of the screening programme. This resulted in a situation where a substantial part of the target population 22 
was not invited (invitation coverage approximatively 50%). Moreover, among the invited population the 23 
willingness to perform the test and participate in diagnostic colonoscopy after a positive result was low.(8) 24 
Considering these major limitations, the short- and long-term outcomes of the current screening 25 
programme should be systematically evaluated in order to provide input for strategic health policy 26 
decisions.(12)  27 
In this study, we performed an economic evaluation of the Hungarian national CRC screening programme 28 
using an established micro-simulation model, investigating also the costs and benefits of potential future 29 
changes to the programme that may help to overcome the abovementioned barriers, including 30 
improvement of the IT platform currently used by GPs and distributing the FIT kits through pharmacies 31 
instead of GPs.  32 
Materials and methods 33 
MISCAN-Colon model 34 
We used the Microsimulation Screening Analysis-Colon (MISCAN-Colon) model (Erasmus University 35 
Medical Center, Rotterdam, The Netherlands) to simulate future outcomes of CRC screening in Hungary. 36 
MISCAN-Colon is a well-established microsimulation model which has been used to inform public health 37 
policies in the US, Canada, Australia and Europe.(6, 13-15) The structure and underlying assumptions of 38 
the model are reported in the Supplementary Materials.  39 
Study population 40 
The model simulated the Hungarian population from 2015 to 2050. The age distribution was based on the 41 
observed age distribution in Hungary in 2018.(16) Supplementary Table 1 provides an overview of the 42 
main model assumptions. In this analysis, our model was specifically calibrated to replicate the age-43 
specific CRC incidence observed in Hungary in 2008-2012 (period before introduction of screening, 44 
Supplementary Figure 1).(17) Incidence and age-specific CRC mortality data were obtained from the 45 
National Screening Registry. As data on CRC stage distribution was not available in Hungary, those model 46 
parameters were calibrated using pre-screening data from a neighboring country (Slovenia, period 2004-47 
2008).(18) The model used all-cause mortality estimates from the 2014 Hungarian life tables.(19) Because 48 
age- and stage-specific information on CRC relative survival was not available in Hungary, we informed 49 
our model with the age- and stage-specific survival observed in The Netherlands during 1999-2003 (5-year 50 
CRC relative survival: 59%). Under these assumptions, the predicted CRC mortality rates showed a 51 
reasonable fit with the Hungarian CRC mortality rates during the period 2008-2012 (Supplementary 52 
Figure 1).(20) 53 
Simulated screening scenarios 54 
In order to evaluate potential future improvements to the programme, we modelled the 2015-2050 55 
Hungarian population under 17 specific screening scenarios as described in Table 1. First, we simulated 56 
no screening (as reference for computing all screening benefits; “No screening”). Second, we simulated 57 
the current screening scenario assuming biennial FIT screening from age 50 to 70 (starting in 2018), with 58 
the FIT kit collected from the GP, in which 50% of target population is invited to FIT screening, and of 59 
those 40% participate (“Current screening strategy”).(8)  60 
Then, we investigated the impact of updating the IT platform of the organized screening programme used 61 
by GPs. We assumed such an improvement would increase GP participation. Specifically, we simulated 62 
three specific scenarios (see Table 1) where we assumed that this policy would result in a direct increase 63 
in invitation coverage because those individuals of the target population whose GPs would newly join the 64 
programme could now be invited for screening. In all these three scenarios, the other characteristics of 65 
the screening programme were simulated as in the current screening scenario.(8)  66 
Finally, we simulated 12 specific screening scenarios to investigate the potential impact of involving 67 
pharmacies instead of GPs in the distribution of the FIT kit. For all these scenarios, biennial FIT screening 68 
starting in 2018 was simulated assuming the entire target population aged from 50 to 70 years was invited 69 
(100% invitation coverage). Full invitation coverage was assumed because it is expected that pharmacies 70 
would collectively join the screening programme under the lead of their advocacy organization, instead 71 
of joining individually as the GPs did. We assumed that the impact of this policy relates to: i) the proportion 72 
of invited individuals who collect the test from the pharmacies; and ii) the proportion of individuals that 73 
perform the test once collected. Specific assumptions for these parameters are listed in Table 1.  74 
All screening scenarios (except for no screening) were simulated assuming 60% adherence in diagnostic 75 
colonoscopy.(8) For individuals with adenomas detected during a diagnostic colonoscopy, surveillance 76 
colonoscopy was offered. Surveillance was simulated every one to five years depending on the number 77 
and size of adenomas, in line with the European guidelines, assuming an adherence of 60%. Assumptions 78 
for test characteristics for FIT and colonoscopy were based on scientific literature (Supplementary Table 79 
1).  80 
CRC screening costs 81 
We performed a cost-effectiveness analysis from a healthcare payer perspective. Costs for CRC screening 82 
were obtained from the National Screening Coordination Department and costs for CRC treatment were 83 
extracted from a study that estimated the net cost of CRC patients’ care at patient-level in Hungary.(21) 84 
All costs were converted to Euro (Supplementary Table 1). Simulating FIT screening, screening costs were 85 
accounted differently according to the simulated screening policy. Simulating current screening, we 86 
accounted a FIT organizational cost (€9.6) for each invited individual, as well as a laboratory cost (€8.9) 87 
and GP reimbursement cost (€4.8) for each FIT performed. When we simulated scenarios with the 88 
updated IT platform, we accounted the same FIT cost as in the current screening. When we simulated the 89 
FIT kit distributed by pharmacies, we accounted a FIT organizational cost (€9.6) for each invited individual, 90 
a pharmacy reimbursement (€2.1) for each FIT kit collected, and a laboratory cost (€8.9) for each FIT 91 
performed. Finally, we included for each screening scenario (except ‘No screening’) two organizational 92 
public investments (€1.85Million in 2018 and €1.9Million in 2020) made by the Hungarian government to 93 
improve the facilities of health service providers performing colonoscopies.  94 
Model outcomes 95 
For each simulated scenario, we computed the effectiveness, i.e. prevented CRC deaths and life-years 96 
gained from screening (LYG), and costs of screening. LYG and costs were discounted by 3.7% annually, as 97 
indicated by the Hungarian guideline of performing economic evaluations.(22) In addition, we computed 98 
the cumulative reduction in CRC mortality due to screening over time and the total undiscounted net costs 99 
(compared to the current screening strategy) per calendar year during the period 2018-2050. 100 
Cost-effectiveness analysis 101 
Cost-effectiveness was evaluated comparing each simulated screening scenario with no screening. 102 
However, incremental cost-effectiveness ratios (ICERs) were estimated as ratio of additional costs and 103 
additional LYG in comparison with the current screening scenario. Cost-effectiveness results were 104 
computed specifically among individuals aged 50 or older during the period 2018-2050 (cost-effectiveness 105 
outcomes in period 2018-2030 were also computed and reported in Supplementary Table 2). 106 
Sensitivity Analyses 107 
We investigated the model parameter uncertainty by performing specific sensitivity analyses. In these, we 108 
assumed: i) a higher participation in the follow-up diagnostic colonoscopy (80%); ii) lower organizational 109 
costs for the FIT test (-10%, -20%, or -50%);  iii) higher or lower GP reimbursement costs (variations in the 110 
actual reimbursement assumed as follows: 50%/20% lower; or 20%/50% higher); and iv) higher or lower 111 
pharmacy reimbursement costs (variations in the actual reimbursement assumed as follows: 50%/20% 112 
lower; or 20%/50% higher). We summarized the results of those analyses in Supplementary Table 3.  113 
Results 114 
In the absence of screening, the model predicted up to 189,600 CRC deaths in Hungary between 2018 and 115 
2050. The current screening strategy was estimated to avoid 2.9% of CRC deaths in the 2018-2030 period 116 
and up to 6.2% in the period 2018-2050 (Table 2, Supplementary Table 2). Up to 7.9 million performed 117 
FITs and 0.3 million colonoscopies were required by the current screening scenario (Table 2).  118 
Updating the IT platform for the GPs reduced CRC mortality in the 2018-2050 period up to 7.7% in the 119 
case of 65% invitation coverage (compared to No screening) (Figure 1), requiring up to 10.2 million 120 
performed FITs and 0.4 million colonoscopies. Screening related costs of the programme increased from 121 
€179 million to €223 million in this scenario. Moreover, annual net costs were estimated to potentially 122 
reach €6.2 million in the period 2018-2030 (Figure 2). Compared to current screening the incremental 123 
costs for every additional life-year (ICER) were €9,701, €10,953 and €10,659 per LYG for the invitation 124 
coverages of 55%, 60% and 65%, respectively.  125 
The model predicted higher reductions in CRC mortality when pharmacies distributed the FIT test (Figure 126 
1). During 2018-2050, the estimated mortality reduction ranged from 11.2% to 16.6% depending on 127 
expected rates of FIT collection and adherence. The highest reduction was observed when 70% of the 128 
invited individuals collected the test with 95% performing the test after picking it up. Distributing the test 129 
through pharmacies was also estimated to avert slightly more CRC deaths in the first decade (2018-2030) 130 
compared to the current screening scenario (Figure 1, Supplementary Table 2).  131 
When 50% of the individuals were simulated to collect the FIT through pharmacies, the model estimated 132 
that up to 18.7 million FITs and 0.7 million colonoscopies were required by the programme, with predicted 133 
ICERs ranging from €9,700 (95% adherence rate) to €11,500 (80% adherence rate) per LYG. When more 134 
individuals collected the FIT from pharmacies, the resources needed for the programme and the costs 135 
increased (Table 2). When 70% of invited individuals collected the test, up to 26 million performed FIT 136 
and 1 million colonoscopies were needed by the programme, with predicted ICERs ranging from €8,000 137 
(95% adherence rate) to €8,700 (80% adherence rate) per LYG. The screening related costs for this 138 
scenario were estimated to be €471 million. Annually, total net costs of the pharmacy scenarios (screening 139 
costs + CRC care costs) ranged from €13 to €37 million, with the highest annual net costs estimated in the 140 
first years after the introduction of the policy (2018-2025; Figure 2).  141 
Compared to the scenarios of updating the IT platform, the scenarios of distributing the FIT tests through 142 
pharmacies resulted in more benefits and lower ICERs when at least 60% of invited individuals collected 143 
the tests. Therefore, these alternatives are more cost-effective options to improve the current system. 144 
Sensitivity analyses 145 
The impact of model parameter uncertainty was investigated for a selected number of scenarios in Figure 146 
2 and for all simulated scenarios in Supplementary Table 3. ICERs were reduced by between €1,000 and 147 
€3,000 per LYG when we assumed a higher participation in diagnostic colonoscopy (i.e. 80%) or a 50% 148 
reduction in the cost of the FIT. Varying the GP reimbursement costs, pharmacy reimbursement costs, or 149 
reducing the FIT costs (by up to 10% or 20%) did not substantially increase or decrease the ICERs.  150 
Discussion 151 
This study provides the first comprehensive evaluation of the newly implemented CRC screening 152 
programme in Hungary, using a widely validated simulation model. We show that even with its important 153 
limitations the current screening programme can ensure a modest mortality reduction in the long term 154 
for the Hungarian population aged 50-100 years. However, we also investigated a number of alternative 155 
scenarios in which the major barriers of the screening programme could (at least partly) be overcome, 156 
leading to even better outcomes: e.g. over 15% mortality reduction with ICERs estimated between €8,000 157 
and €8,400 per LYG in some scenarios. These ICERs are well below the current Hungarian threshold for 158 
cost-effectiveness in drug reimbursement (health technologies with an ICER above 3 times the GDP per 159 
capita [~€40 000] / quality-adjusted life years are considered not cost-effective).(22) The national 160 
guideline for health technology assessment does not define cost-effectiveness thresholds for other health 161 
technologies such as public health programmes. 162 
Our study presumed that different invitation strategies lead to a variation in participation rate (i.e. 163 
different % of attenders among annual target population shown in Table 1). The key benefit of the 164 
pharmacy scenario would not necessarily be the increased attendance rate of the invited individuals, but 165 
the higher coverage, which could lead to the invitation of the full target population for the screening. An 166 
interesting trade-off was investigated in this respect, where we assumed a lower unit cost per FIT test for 167 
pharmacies compared to GPs, with a more frequent occurrence as pharmacies would receive the funding 168 
for every distributed KIT whereas GPs received it after every performed test. The ICERs showed that most 169 
scenarios of distributing the FIT tests through pharmacies were more favorable, indicating that the costs 170 
of reimbursing more tests (even some unused) would be outweighed by the higher benefits expressed in 171 
LYG.  172 
As the effectiveness of screening is directly associated with the level of screening participation, it is also 173 
reasonable to expect that screening costs (i.e. test and following investigation costs) increase as well. 174 
However, our model also estimated elevated costs due to CRC care (both in the short and long term). This 175 
is counterintuitive as detecting CRC at an earlier stage should be associated with less expensive 176 
treatments and hospitalization costs, as shown in previous cost-effectiveness analyses (also carried out 177 
with MISCAN-Colon).(23-25) This result can be explained by the fact that costs did not vary substantially 178 
according to CRC care phase: costs accounted in the last year before death (from CRC or other causes) 179 
were in line with those for ongoing/continuous care. In previous cost-effectiveness analyses, terminal care 180 
costs were from 10- to 50-fold higher than those assumed for continuous care.(23-25) Thus, when a CRC 181 
case was detected early at a lower stage in our analysis, the model accounted lower CRC terminal care 182 
costs (death averted) than in the previous analyses but higher costs for CRC ongoing care (because 183 
accounted for each LYG for those with a screen-detected CRC).  184 
Besides the results concerning the cost-benefit ratio of the investigated scenarios, other estimations of 185 
our economic evaluation, such as number of tests performed or number of follow-up examinations 186 
executed, are important for capacity planning purposes (e.g. human resources, organizational capacities). 187 
Scenarios in our study also indicated an increasing number of colonoscopies to be performed in the future. 188 
These estimations could help healthcare policymakers to judge whether the two public investments made 189 
in 2018 and 2020 to improve the facilities for performing colonoscopies were sufficient, or whether 190 
further investment is required in the future.  191 
In the literature, CRC screening programmes have been proven to be highly cost effective, ensuring major 192 
health gains at acceptable costs.(7, 26, 27) However, it is not clear which screening strategy is preferable 193 
for a population-based CRC screening programme, as costs of screening, screening adherence, test 194 
sensitivity, and costs of CRC treatment have a substantial impact on overall cost-effectiveness and are 195 
highly dependent on country settings.(28) For example in a previous economic evaluation, Arrospide et al 196 
found that, in the first years of the CRC FIT screening programme in the Basque country (64.3% screening 197 
adherence), €69.2 million were necessary (on average) to annually fund the programme.(26) In our budget 198 
analysis, we found that in Hungary the current FIT screening programme would need from €14 to €20 199 
million of annual funds (Supplementary Table 4) during its first years assuming that 20% of the individuals 200 
in the target population participated in screening.  201 
In the scenarios where pharmacies would distribute the tests, we projected a relatively large total net cost 202 
compared to the current screening strategy (ranging from an extra €13 to €37 million, see Figure 2). 203 
However, these estimates include not only the screening-related costs but also the increased costs in CRC 204 
care. Still, such an increase in costs would require a significant investment considering the Hungarian 205 
public health perspective. To put this amount into a local context, about €85-90 million were nominated 206 
for public health in the annual national budget in Hungary (not counting the less centralized regional or 207 
local-level spending on public health). This amount covered mainly national-level public health 208 
programmes, interventions and initiatives.  209 
Our study has a number of limitations. First, some of the input data for the modelling were not available 210 
for Hungary, and therefore data from other countries were used. Second, our screening scenarios are 211 
based on the experience and knowledge of experts from Hungary, and it is difficult to judge whether they 212 
are realistic to achieve in real life. However, we performed extensive analysis with multiple scenarios and 213 
sensitivity analyses, so the results should be useful under a wide range of circumstances. Third, there were 214 
certain cost elements which were not possible to estimate and include in the calculations (i.e. additional 215 
costs of pharmacies to implement screening-related tasks or additional investments needed to improve 216 
the current IT platform used by the GPs), and therefore future screening scenarios might underestimate 217 
costs. Moreover, our analysis did not include additional alternative options of invitation, such as sending 218 
the FIT kit by post. However, with the low participation in CRC screening currently observed in Hungary, 219 
introducing this last option may not be opportune. Fourth, the benefits of screening in economic 220 
evaluations are frequently expressed in quality-adjusted life years. (29, 30) However, quality-of-life data 221 
were not available in our case and, therefore, LYGs were used. Finally, the MISCAN-Colon model simulates 222 
the natural history of CRC through the adenoma-carcinoma sequence and does not consider adenoma 223 
histology (villous histology or advanced atypia) or sessile serrated polyps.  224 
The results of our study should serve as the basis for further improvement of the current CRC screening 225 
programme in Hungary. Switching to the distribution of FIT kits through pharmacies instead of GPs in the 226 
organized screening programme seems to be a justifiable and important step towards achieving higher 227 
invitation coverage. However, it should be noted that such a change might be difficult to achieve without 228 
the collaboration and support of GPs who are currently the key stakeholders. Although the test kits would 229 
not be distributed by the GPs in this scenario, their role in the screening process would still be crucial as 230 
they would still be responsible for the coordination of the patient pathway from the screening to patient 231 
care. Thus, appropriate communication with the GPs is an important initial element for implementing 232 
future changes in the screening programme. On the other hand, pharmacies should also be prepared to 233 
implement screening-related activities into their current practice.   234 
Conclusions 235 
Despite the important organizational limitations, the current national CRC screening programme in 236 
Hungary can ensure modest mortality reduction in the long-term for the population aged between 50 and 237 
100. However, this study shows that in order to fully exploit the benefits of the programme further 238 
improvements are required; for instance, changes to the current IT platform or involving pharmacies in 239 
the test distribution mechanism. We estimated that alternative scenarios reflecting these changes have 240 
favorable cost-benefit ratios.241 
Table 1. Overview of the assumptions for each simulated screening strategy. 242 








Adherence to screening 
(% of attenders in screening among invited) 









% performing FIT 
(among those who 
collected the test) 
 No screening - - - - - 
 Current screening 
(Biennial FIT, age 50-70) 
50% - - 40% 20% 
      
a. Strategies improving IT platform for GPs 
(40% of adherence in screening):      
GP1. Invitation coverage: 55% 55% - - 40% 22% 
GP2. Invitation coverage: 60% 60% - - 40% 24% 
GP3. Invitation coverage: 65% 65% - - 40% 26% 
      
b. Strategies of distributing FIT tests 
through pharmacies 
(100% invitation coverage):      
- 50% collected the FIT:* 
80% performed the test 100% 50% 80% 40% 40% 
85% performed the test 100% 50% 85% 42.5% 42.5% 
90% performed the test 100% 50% 90% 45% 45% 
95% performed the test 100% 50% 95% 47.5% 47.5% 
      
- 60% collected the FIT:* 
80% performed the test 100% 60% 80% 48% 48% 
85% performed the test 100% 60% 85% 51% 51% 
90% performed the test 100% 60% 90% 54% 54% 
95% performed the test 100% 60% 95% 57% 57% 
      
- 70% collected the FIT:* 
80% performed the test 100% 70% 80% 56% 56% 
85% performed the test 100% 70% 85% 59.5% 59.5% 
90% performed the test 100% 70% 90% 63% 63% 
95% performed the test 100% 70% 95% 66.5% 66.5% 
+ All policies were simulated in 2018; 243 
* We assumed a 40% adherence in screening among invited simulating scenarios where the FIT kit was collected through GPs; when we simulated scenarios 244 
of distributing the FIT kits through pharmacies, adherence in screening was the result of the multiplication between proportion of invited individuals that 245 
collected the test from pharmacies and proportion of individuals that performed the test among those that collected the kit. 246 
Table 2. Colorectal cancer screening simulated outcomes (x10,000, for individuals in the total 
Hungarian population aged 50-100 years-old in 2018-2050) per policy implemented. 





















 No screening 18.96 - - - - 0.00 585339.0 588170.4 - 
 Current screening 




597437.0 620968.1 Reference 
          
a. Strategies improving IT platform 
for GPs (40% of adherence in 
screening):      
  
  
GP1. Invitation coverage: 55% 17.68 6.75 5.17 866.15 35.35 19390.03 599274.7 624557.4 9701 
GP2. Invitation coverage: 60% 17.59 7.23 5.46 946.02 38.64 20859.73 601191.6 628197.2 10953 
GP3. Invitation coverage: 65% 17.50 7.70 5.80 1025.83 41.89 22289.17 602941.8 631626.9 10659 
          
b. Strategies of distributing FIT 
tests through pharmacies 
(100% invitation coverage):      
  
  
- 50% collected the FIT:* 




616183.2 657783.6 11541 
85% performed the test 16.72 11.81 8.45 1684.98 68.24 34812.52 617079.3 660323.2 10782 
90% performed the test 16.62 12.34 8.87 1780.10 71.58 36148.35 617922.7 662755.9 10267 
95% performed the test 16.52 12.87 9.34 1874.78 74.95 37436.91 618740.3 665115.3 9724 
          
- 60% collected the FIT:* 




618898.4 665619.5 9644 
85% performed the test 16.37 13.66 9.96 2006.85 79.52 39357.19 619850.1 668490.4 9210 
90% performed the test 16.27 14.19 10.43 2120.12 83.19 40938.67 620664.9 671162.6 8916 
95% performed the test 16.15 14.82 10.90 2232.05 86.98 42456.27 621443.8 673742.4 8652 
          
- 70% collected the FIT:* 




621176.1 672624 8682 
85% performed the test 16.05 15.35 11.31 2325.00 90.11 43547.29 622219.7 675841.8 8429 
  
90% performed the test 15.93 15.98 11.87 2454.36 94.38 45332.74 622897.1 678626.7 8155 
95% performed the test 15.81 16.61 12.38 2582.72 98.64 47059.05 623723.7 681499.5 7986 
CRC = Colorectal cancer; FIT = Fecal Immunochemical Test; LYG = Life-years gained from screening; ICER = Incremental Cost-
Effectiveness Ratio; COL = Colonoscopy; Scr. Participation = participation rate in FIT screening; FIT screening was simulated 
assuming a biennial screening interval between age 50 and 70 years. 
* percentage of invited individuals that collected the FIT kit through the pharmacies, the proportion of performed test is 
meant as the proportion of individuals that performed the test among those who collected the FIT kit through pharmacies;  
† ICER were computed as ratio between incremental costs and benefits (LYG) compared to current screening; ICER values are 
not expressed in x10,000 in this table 
‡ CRC deaths were not discounted; 
║ Compared to no screening; 
** Total costs included costs for primary screening, for CRC care and treatment, for CRC diagnosis due to symptoms (no 
screen-detected CRCs), for diagnostic follow-up investigations, and for colonoscopy surveillance.   
 
Figure 1. Cumulative colorectal cancer mortality reduction due to screening in Hungary for individuals aged 50 years or older and per simulated screening 
scenario. Note: *current screening: biennial FIT, 50-70, invitation coverage = 50% and screening adherence among invited = 40%; ** we assumed full invitation coverage in scenarios where 
the FIT kits were distributed through pharmacies 
 
Figure 2. Estimated total annual net costs in Hungary among individuals aged 50 years or older and per simulated screening scenario (net costs compared to 
the current screening scenario). Note: *current screening: biennial FIT, 50-70, invitation coverage = 50% and screening adherence among invited = 40%; ** we assumed full invitation 
coverage in scenarios where the FIT kits were distributed through pharmacies 
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